Boone Capital Management LLC purchased a new position in Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 455,605 shares of the company's stock, valued at approximately $14,242,000. Tango Therapeutics makes up about 3.3% of Boone Capital Management LLC's portfolio, making the stock its 13th biggest holding. Boone Capital Management LLC owned approximately 0.27% of Tango Therapeutics as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Allworth Financial LP purchased a new stake in Tango Therapeutics during the 2nd quarter worth approximately $35,000. Global Retirement Partners LLC acquired a new position in shares of Tango Therapeutics in the 4th quarter valued at approximately $35,000. Dynamic Technology Lab Private Ltd raised its position in shares of Tango Therapeutics by 139.7% in the 1st quarter. Dynamic Technology Lab Private Ltd now owns 25,801 shares of the company's stock valued at $35,000 after purchasing an additional 15,037 shares in the last quarter. Legal & General Group Plc boosted its stake in shares of Tango Therapeutics by 30.7% during the 2nd quarter. Legal & General Group Plc now owns 6,985 shares of the company's stock valued at $36,000 after buying an additional 1,640 shares during the last quarter. Finally, ANTIPODES PARTNERS Ltd purchased a new position in shares of Tango Therapeutics during the 4th quarter valued at approximately $40,000. Hedge funds and other institutional investors own 78.99% of the company's stock.
Insider Activity at Tango Therapeutics
In related news, insider Adam Crystal sold 27,000 shares of the stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $29.59, for a total value of $798,930.00. Following the sale, the insider owned 115,743 shares of the company's stock, valued at $3,424,835.37. This trade represents a 18.92% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 6.50% of the company's stock.
Tango Therapeutics Price Performance
NASDAQ:TNGX opened at $25.47 on Thursday. The firm has a market capitalization of $4.29 billion, a P/E ratio of -29.96 and a beta of 1.16. The business has a 50 day simple moving average of $27.90 and a 200 day simple moving average of $23.04. Tango Therapeutics, Inc. has a 12-month low of $6.25 and a 12-month high of $34.39.
Tango Therapeutics (NASDAQ:TNGX - Get Free Report) last issued its earnings results on Tuesday, August 11th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.05). Research analysts anticipate that Tango Therapeutics, Inc. will post -1.38 EPS for the current fiscal year.
Analyst Ratings Changes
A number of analysts recently issued reports on the stock. Mizuho lifted their price target on shares of Tango Therapeutics from $36.00 to $40.00 and gave the stock an "outperform" rating in a research note on Friday, July 17th. Wall Street Zen downgraded shares of Tango Therapeutics from a "sell" rating to a "strong sell" rating in a research note on Saturday, August 15th. Weiss Ratings raised shares of Tango Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a report on Tuesday, August 11th. UBS Group set a $55.00 target price on shares of Tango Therapeutics in a research report on Thursday, May 14th. Finally, Jefferies Financial Group upgraded Tango Therapeutics from a "hold" rating to a "buy" rating and lifted their price target for the stock from $27.00 to $60.00 in a research note on Thursday, June 25th. Thirteen research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $43.46.
Get Our Latest Research Report on Tango Therapeutics
About Tango Therapeutics
(
Free Report)
Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.
The company's lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.
Recommended Stories
Want to see what other hedge funds are holding TNGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Tango Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tango Therapeutics wasn't on the list.
While Tango Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead.
This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
